-
Study aim
-
The aim of this study is to investigate several parameters related to oxidative stress and systemic inflammation, especially homocysteine in peritoneal dialysis patients receiving omega-3 fatty acids.
-
Design
-
A concealed, randomized, blinded, sham-controlled clinical trial with a parallel-group design of 100 patients, block randomization was used for randomization.
-
Settings and conduct
-
Individuals who meet the inclusion criteria will be randomly assigned to the intervention and control groups. Demographic and clinical characteristics of patients will be recorded. Patients in the omega-3 soft capsule intervention group will receive one gram with each meal for 8 weeks. Participants in the control group will receive a placebo. Serum lipid profile, serum albumin level, ESR level, hs-CRP level and serum homocysteine level were measured in all patients before the start of the study and after 8 weeks at the end of the study. Finally, using statistical tests, the average of the measured tests will be compared between the two groups. Researchers and patients are blinded
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: age 18 years and older, ESRD patients undergoing peritoneal dialysis, informed consent to participate in this study
Exclusion criteria: history of malignancy, patients with a history of known allergies to products containing omega-3, coagulation disorders and use of anticoagulants, use of any antioxidant or anti-inflammatory drugs, severe systemic diseases or infectious diseases
-
Intervention groups
-
For the intervention group omega-3 capsules (120 mg DHA plus 180 mg EPA) at a dose of 3000 mg per day, ie 1000 mg with each meal per day for 8 weeks will be prescribed and the control group will receive a placebo.
-
Main outcome variables
-
Homocysteine levels and inflammatory and oxidative markers